Technology area: Biotechnology & Pharmaceuticals
30 pending office actions • 22 art units • 28 examiners • 0 of 30 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days
Cedars-Sinai Medical Center has 31 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 29 distinct examiners and 23 distinct art units, indicating extensive distribution across examination personnel and technical groups. The difference between pending matters and examiners shows that only limited examiner overlap is present.
FERNANDEZ, SUSAN EMILY is the busiest examiner, with 2 pending matters. No single examiner dominates the docket, so portfolio oversight should prioritize consistent claim and disclosure positions while tailoring arguments to the separate art-unit environments.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (17%) |
| §103 only | 6 (20%) |
| §112 only | 5 (17%) |
| Double-patenting + other | 2 (7%) |
| Multi-statute (no §101) | 12 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNANDEZ, SUSAN EMILY | 2 | 52.3% | +60.9% |
| WEHBE, ANNE MARIE SABRINA | 2 | 57.3% | +43.3% |
| DUNHAM, JASON B | 1 | 26.8% | +27.3% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| WILDER, CYNTHIA B | 1 | 70.8% | +27.0% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| NG, JONATHAN K | 1 | 35.6% | +14.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | STONEBRAKER, ALYSSA RAE | 31d overdue |
| 18352622 | NOVEL AND EFFICIENT METHOD FOR REPROGRAMMING IMMORTALIZED LYMPHOBLASTOID CELL LINES TO INDUCED PLURIPOTENT STEM CELLS | WEHBE, ANNE MARIE SABRINA | 16d overdue |
| 19123191 | METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS | DUNHAM, JASON B | — |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | LANKFORD JR, LEON B | — |
| 18892854 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO CISPLATIN | KENYON, JOHN S | — |
| 18845311 | METHODS AND COMPOSITIONS FOR SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE GUT MICROBIOME | FERNANDEZ, SUSAN EMILY | — |
| 18706126 | KITS AND METHODS FOR QUANTITATIVE ASSESSMENT AND ENRICHMENT OF EXTRACHROMOSOMAL CIRCULAR DNA | CASH, KAILEY ELIZABETH | — |
| 18647340 | RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF | WILDER, CYNTHIA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17565834 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS | FERNANDEZ, SUSAN EMILY | 112d overdue |
| 18352622 | NOVEL AND EFFICIENT METHOD FOR REPROGRAMMING IMMORTALIZED LYMPHOBLASTOID CELL LINES TO INDUCED PLURIPOTENT STEM CELLS | WEHBE, ANNE MARIE SABRINA | 16d overdue |
| 19123191 | METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS | DUNHAM, JASON B | — |
| 18862311 | RIFAXIMIN AND N-ACETYL CYSTEINE FORMULATIONS | GEMBEH, SHIRLEY V | — |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | LANKFORD JR, LEON B | — |
| 18892854 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO CISPLATIN | KENYON, JOHN S | — |
| 18845311 | METHODS AND COMPOSITIONS FOR SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE GUT MICROBIOME | FERNANDEZ, SUSAN EMILY | — |
| 18706126 | KITS AND METHODS FOR QUANTITATIVE ASSESSMENT AND ENRICHMENT OF EXTRACHROMOSOMAL CIRCULAR DNA | CASH, KAILEY ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1634 | 3 |
| 1682 | 3 |
| 3619 | 2 |
| 1645 | 2 |
| 3686 | 1 |
| 1615 | 1 |
| 1657 | 1 |
| 1683 | 1 |
| 1681 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19123191 | METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS | DUNHAM, JASON B | 3686 | §101§103§112 | Non-Final OA | — | Pending | Apr 22, 2025 |
| 18862311 | RIFAXIMIN AND N-ACETYL CYSTEINE FORMULATIONS | GEMBEH, SHIRLEY V | 1615 | §103 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | LANKFORD JR, LEON B | 1657 | §102§103 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18892854 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO CISPLATIN | KENYON, JOHN S | — | §102§112Other | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18845311 | METHODS AND COMPOSITIONS FOR SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE GUT MICROBIOME | FERNANDEZ, SUSAN EMILY | — | §102§103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18706126 | KITS AND METHODS FOR QUANTITATIVE ASSESSMENT AND ENRICHMENT OF EXTRACHROMOSOMAL CIRCULAR DNA | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18647340 | RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF | WILDER, CYNTHIA B | 1681 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | BUNNER, BRIDGET E | 1647 | §102§112Other | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18580962 | METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS | NG, JONATHAN K | 3619 | §101§103 | Final Rejection | — | Pending | Jan 19, 2024 |
| 18386537 | METHODS FOR TREATING NEPHROTIC SYNDROME | HINES, JANA A | 1645 | §103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18235945 | ENDOSCOPIC FLUID ASPIRATION DEVICE | YOON, CHANEL J | 3791 | §103 | Non-Final OA | 60d overdue | Pending | Aug 21, 2023 |
| 18546938 | COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | SHUPE, ELIZABETH A | 1643 | §103DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18546947 | ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG | STEPHENS, AMELIA CAROLE | 1645 | §103DP | Final Rejection | 50d | Pending | Aug 17, 2023 |
| 18273161 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | VASSELL, MEREDITH ABBOTT | 1687 | §101§103Other | Final Rejection | — | Pending | Jul 19, 2023 |
| 18352622 | NOVEL AND EFFICIENT METHOD FOR REPROGRAMMING IMMORTALIZED LYMPHOBLASTOID CELL LINES TO INDUCED PLURIPOTENT STEM CELLS | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112 | Final Rejection | 16d overdue | Pending | Jul 14, 2023 |
| 18326912 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | HUDSON, AMY ROSE | 1636 | §112 | Final Rejection | 46d | Pending | May 31, 2023 |
| 18310796 | METHODS FOR TREATING SHORT BOWEL SYNDROME AND/OR HIGH OUTPUT OSTOMY | VU, JAKE MINH | 1618 | §102§103§112Other | Non-Final OA | — | Pending | May 02, 2023 |
| 18008150 | METHODS AND SYSTEMS FOR MEASURING POST-OPERATIVE DISEASE RECURRENCE | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112Other | Final Rejection | — | Pending | Dec 02, 2022 |
| 18008146 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | GOLDBERG, JEANINE ANNE | 1682 | §101§112DP | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17924010 | DEVICES, ASSAYS AND METHODS OF TESTING PREECLAMPSIA | GIERE, REBECCA M | 1677 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17921174 | ISOLATION AND FUNCTIONAL ANALYSIS OF EPITHELIAL PROGENITOR CELLS FROM THE HUMAN LUNG | ABBOTT, KODYE LEE | 1634 | §112 | Final Rejection | — | Pending | Oct 25, 2022 |
| 17912809 | INTERNAL ULTRAVIOLET THERAPY | HOLMES, REX R | 3796 | §103 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17633505 | METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | — | Pending | Feb 07, 2022 |
| 17633067 | METHODS OF IMPROVING ORGAN FUNCTION | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | Feb 04, 2022 |
| 17565834 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS | FERNANDEZ, SUSAN EMILY | 1651 | §112 | Final Rejection | 112d overdue | Pending | Dec 30, 2021 |
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112 | Non-Final OA | 31d overdue | Pending | Aug 31, 2021 |
| 17334109 | METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | WHALEY, PABLO S | 3619 | §112 | Final Rejection | 20d | Pending | May 28, 2021 |
| 17043888 | METHODS FOR IN VITRO EXPANSION OF ADULT TISSUE STEM CELLS | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Non-Final OA | — | Pending | Sep 30, 2020 |
| 16832977 | GUT BACTERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METHODS THEREWITH IN DETECTING ILEAL FIBROSIS | SITTON, JEHANNE SOUAYA | 1682 | §103 | Non-Final OA | — | Pending | Mar 27, 2020 |
| 16515458 | HIGHLY MULTIPLEXED AND MASS SPECTROMETRY BASED METHODS TO MEASURING 72 HUMAN PROTEINS | MARTIN, PAUL C | 1653 | §101§103§112 | Non-Final OA | — | Pending | Jul 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCedars-Sinai Medical Center has 30 pending office actions as of October 2026, spread across 22 art units and 28 examiners.
Susan Emily Fernandez has the most, with 2 of Cedars-Sinai Medical Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
